(NX) Quanex Building Products - Overview
Sector: Industrials | Industry: Building Products & Equipment | Exchange: NYSE (USA) | Market Cap: 758m USD | Total Return: 2.8% in 12m
Avg Turnover: 5.66M
EPS Trend: -79.9%
Qual. Beats: -1
Rev. Trend: 88.8%
Qual. Beats: 0
Warnings
Interest Coverage Ratio -3.3 is critical
Altman Z'' 0.87 < 1.0 - financial distress zone
Choppy
Tailwinds
Shakeout
Quanex Building Products (NYSE: NX) is a manufacturer of engineered components for original equipment manufacturers (OEMs) within the global building products industry. Founded in 1927 and headquartered in Houston, Texas, the company operates across North America, Europe, and Asia, specializing in energy-efficient solutions such as insulating glass spacers, vinyl profiles, and window and door hardware. Its portfolio also includes solar panel sealants, decking, and metal and wood products distributed through a mix of direct sales and independent agents.
The company operates within the cyclical building products sector, where demand is heavily influenced by residential construction starts and the repair and remodel (R&R) market. As an OEM supplier, Quanex functions as an essential link in the supply chain, providing specialized materials that allow window and door manufacturers to meet increasingly stringent thermal performance and energy efficiency standards.
For a more detailed analysis of the companys financial health and valuation metrics, consider reviewing the data available on ValueRay.
- Residential housing starts and remodeling activity drive core window component demand
- Raw material price volatility for vinyl and aluminum impacts gross margins
- Expansion into solar sealants and commercial access diversifies revenue streams
- Adoption of energy-efficient building codes boosts demand for high-performance spacers
- Integration of recent acquisitions shifts operational scale and international market exposure
| Net Income: -240.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 3.30 > 1.0 |
| NWC/Revenue: 17.48% < 20% (prev 22.16%; Δ -4.68% < -1%) |
| CFO/TA 0.08 > 3% & CFO 157.2m > Net Income -240.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.31 > 1.5 & < 3 |
| Outstanding Shares: last quarter (45.5m) vs 12m ago -3.32% < -2% |
| Gross Margin: 26.06% > 18% (prev 0.24%; Δ 2.58k% > 0.5%) |
| Asset Turnover: 87.97% > 50% (prev 64.79%; Δ 23.17% > 0%) |
| Interest Coverage Ratio: -3.30 > 6 (EBITDA TTM -75.2m / Interest Expense TTM 54.0m) |
| A: 0.16 (Total Current Assets 568.7m - Total Current Liabilities 245.8m) / Total Assets 1.98b |
| B: 0.08 (Retained Earnings 157.0m / Total Assets 1.98b) |
| C: -0.08 (EBIT TTM -178.2m / Avg Total Assets 2.10b) |
| D: 0.11 (Book Value of Equity 133.1m / Total Liabilities 1.25b) |
| Altman-Z'' = 0.87 = B |
| DSRI: 0.87 (Receivables 189.2m/169.6m, Revenue 1.85b/1.44b) |
| GMI: 0.92 (GM 26.06% / 24.08%) |
| AQI: 0.80 (AQ_t 0.42 / AQ_t-1 0.52) |
| SGI: 1.28 (Revenue 1.85b / 1.44b) |
| TATA: -0.20 (NI -240.0m - CFO 157.2m) / TA 1.98b) |
| Beneish M = -3.32 (Cap -4..+1) = AA |
As of May 24, 2026, the stock is trading at USD 17.18 with a total of 316,415 shares traded.
Over the past week, the price has changed by +6.62%,
over one month by -12.84%,
over three months by -18.79% and
over the past year by +2.79%.
Quanex Building Products has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy NX.
- StrongBuy: 2
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 28 | 63% |
P/S = 0.4107
P/B = 1.2736
P/EG = 0.7232
Revenue TTM = 1.85b USD
EBIT TTM = -178.2m USD
EBITDA TTM = -75.2m USD
Long Term Debt = 678.6m USD (from longTermDebt, last quarter)
Short Term Debt = 45.3m USD (from shortTermDebt, last quarter)
Debt = 1.08b USD (from shortLongTermDebtTotal, last quarter) + Leases 185.4m
Net Debt = 1.02b USD (calculated: Debt 1.08b - CCE 62.3m)
Enterprise Value = 1.77b USD (758.4m + Debt 1.08b - CCE 62.3m)
Interest Coverage Ratio = -3.30 (Ebit TTM -178.2m / Interest Expense TTM 54.0m)
EV/FCF = 18.70x (Enterprise Value 1.77b / FCF TTM 94.9m)
FCF Yield = 5.35% (FCF TTM 94.9m / Enterprise Value 1.77b)
FCF Margin = 5.14% (FCF TTM 94.9m / Revenue TTM 1.85b)
Net Margin = -13.00% (Net Income TTM -240.0m / Revenue TTM 1.85b)
Gross Margin = 26.06% ((Revenue TTM 1.85b - Cost of Revenue TTM 1.37b) / Revenue TTM)
Gross Margin QoQ = 18.16% (prev 28.08%)
Tobins Q-Ratio = 0.90 (Enterprise Value 1.77b / Total Assets 1.98b)
Interest Expense / Debt = 5.01% (Interest Expense 54.0m / Debt 1.08b)
Taxrate = 21.0% (US default 21%)
NOPAT = -140.8m (EBIT -178.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.31 (Total Current Assets 568.7m / Total Current Liabilities 245.8m)
Debt / Equity = 1.48 (Debt 1.08b / totalStockholderEquity, last quarter 730.4m)
Debt / EBITDA = -13.50 (negative EBITDA) (Net Debt 1.02b / EBITDA -75.2m)
Debt / FCF = 10.70 (Net Debt 1.02b / FCF TTM 94.9m)
Total Stockholder Equity = 793.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -11.43% (Net Income -240.0m / Total Assets 1.98b)
RoE = -30.23% (Net Income TTM -240.0m / Total Stockholder Equity 793.9m)
RoCE = -12.10% (EBIT -178.2m / Capital Employed (Equity 793.9m + L.T.Debt 678.6m))
RoIC = -8.21% (negative operating profit) (NOPAT -140.8m / Invested Capital 1.72b)
WACC = 6.99% (E(758.4m)/V(1.84b) * Re(11.29%) + D(1.08b)/V(1.84b) * Rd(5.01%) * (1-Tc(0.21)))
Discount Rate = 11.29% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 35.96 | Cagr: 15.31%
[DCF] Terminal Value 77.97% ; FCFF base≈70.3m ; Y1≈80.5m ; Y5≈118.5m
[DCF] Fair Price = 16.72 (EV 1.78b - Net Debt 1.02b = Equity 768.0m / Shares 45.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -79.94 | EPS CAGR: -11.57% | SUE: -1.02 | # QB: -1
Revenue Correlation: 88.78 | Revenue CAGR: 24.42% | SUE: 0.45 | # QB: 0
EPS current Quarter (2026-07-31): EPS=0.66 | Chg30d=-12.62% | Revisions=-43% | Analysts=4
EPS current Year (2026-10-31): EPS=1.69 | Chg30d=-15.94% | Revisions=-43% | GrowthEPS=-26.6% | GrowthRev=+1.4%
EPS next Year (2027-10-31): EPS=2.15 | Chg30d=-6.74% | Revisions=-33% | GrowthEPS=+27.1% | GrowthRev=+1.7%
[Analyst] Revisions Ratio: -43%